DE60318900D1 - Nukleinsäuren, polypeptide und verfahren zur modulierung der apoptose - Google Patents

Nukleinsäuren, polypeptide und verfahren zur modulierung der apoptose

Info

Publication number
DE60318900D1
DE60318900D1 DE60318900T DE60318900T DE60318900D1 DE 60318900 D1 DE60318900 D1 DE 60318900D1 DE 60318900 T DE60318900 T DE 60318900T DE 60318900 T DE60318900 T DE 60318900T DE 60318900 D1 DE60318900 D1 DE 60318900D1
Authority
DE
Germany
Prior art keywords
apoptosis
eif
specific eif
polypeptides
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60318900T
Other languages
German (de)
English (en)
Inventor
John E Thompson
Catherine Taylor
Dominic Cliche
Charles Dinarello
Leonid Reznikov
Benjamin Pomerantz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eloxx Pharmaceuticals Inc
Original Assignee
Senesco Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senesco Technologies Inc filed Critical Senesco Technologies Inc
Application granted granted Critical
Publication of DE60318900D1 publication Critical patent/DE60318900D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60318900T 2002-10-23 2003-10-22 Nukleinsäuren, polypeptide und verfahren zur modulierung der apoptose Expired - Lifetime DE60318900D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/277,969 US7217517B2 (en) 2001-07-23 2002-10-23 Nucleic acids, polypeptides, and methods for modulating apoptosis
PCT/US2003/033463 WO2004037984A2 (en) 2002-10-23 2003-10-22 Nucleic acids, polypeptides, and methods for modulating apoptosis

Publications (1)

Publication Number Publication Date
DE60318900D1 true DE60318900D1 (de) 2008-03-13

Family

ID=32174556

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60318900T Expired - Lifetime DE60318900D1 (de) 2002-10-23 2003-10-22 Nukleinsäuren, polypeptide und verfahren zur modulierung der apoptose

Country Status (12)

Country Link
US (1) US7217517B2 (enExample)
EP (1) EP1578452B1 (enExample)
JP (1) JP4890763B2 (enExample)
KR (1) KR20050046015A (enExample)
CN (1) CN1732018B (enExample)
AT (1) ATE384740T1 (enExample)
AU (1) AU2003301585B2 (enExample)
CA (1) CA2503442C (enExample)
DE (1) DE60318900D1 (enExample)
NZ (1) NZ540105A (enExample)
TW (1) TWI324070B (enExample)
WO (1) WO2004037984A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166467B2 (en) * 2001-07-23 2007-01-23 Senesco Technologies, Inc. Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
NZ542665A (en) * 2003-03-05 2008-05-30 Senesco Technologies Inc Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1
US20140371299A1 (en) * 2004-06-07 2014-12-18 Senesco Technologies, Inc. Use of Apoptosis-Specific elF-5A siRNA to Down Regulate Expression of Proinflammatory Cytokines to Treat Sepsis
AR049999A1 (es) * 2004-07-20 2006-09-20 Senesco Technologies Inc Uso de siarn de eif-5a y polinucleotidos antisentido especificos de la apoptosis para inhibir/suprimir una respuesta inflamatoria.
EP1959010A3 (en) * 2004-12-03 2009-02-25 Senesco Technologies, Inc. Apoptosis-specific eif-5A and polynucleotides encoding same
JP5205058B2 (ja) * 2004-12-03 2013-06-05 セネスコ テクノロジーズ，インコーポレイティド 種子の収量を増大させる方法
WO2009144933A1 (ja) * 2008-05-27 2009-12-03 国立大学法人東京大学 アポトーシス誘導薬
JP6639408B2 (ja) 2014-11-07 2020-02-05 藤倉化成株式会社 デオキシハイプシン・シンターゼ遺伝子を指標として用いる動脈硬化及びがんの検出方法
JP2021526837A (ja) * 2018-06-12 2021-10-11 アンジーエックス・インコーポレーテッド 抗体−オリゴヌクレオチドコンジュゲート
CN114231551B (zh) * 2021-12-24 2023-09-29 云南大学 蛋白在促进昆虫淋巴细胞凋亡和/或防治害虫中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5344846A (en) 1992-12-30 1994-09-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells
CZ255397A3 (cs) * 1995-02-13 1998-02-18 Novartis Ag Mutantní proteiny, způsob jejich přípravy, farmaceutické prostředky, které je obsahují, a jejich použití
US5849587A (en) 1995-06-09 1998-12-15 Cornell Research Foundation, Inc. Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells
WO1999001551A2 (en) 1997-06-30 1999-01-14 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel inhibitor of cellular proliferation
US6538182B1 (en) 1999-07-06 2003-03-25 Senesco, Inc. DNA encoding a plant deoxyhypusine synthase, a plant eukaryotic initiation factor 5A, transgenic plants and a method for controlling senescence programmed and cell death in plants
WO2001010906A1 (en) 1999-08-06 2001-02-15 Pharmacia & Upjohn Company Crystallization and structure determination of staphylococcus aureus elongation factor p
US7166467B2 (en) 2001-07-23 2007-01-23 Senesco Technologies, Inc. Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis

Also Published As

Publication number Publication date
CA2503442C (en) 2014-02-18
EP1578452A4 (en) 2006-01-11
TW200501988A (en) 2005-01-16
AU2003301585B2 (en) 2009-08-20
WO2004037984A3 (en) 2005-04-14
CN1732018A (zh) 2006-02-08
EP1578452A2 (en) 2005-09-28
CN1732018B (zh) 2014-09-10
US20030144238A1 (en) 2003-07-31
CA2503442A1 (en) 2004-05-06
NZ540105A (en) 2006-10-27
ATE384740T1 (de) 2008-02-15
US7217517B2 (en) 2007-05-15
EP1578452B1 (en) 2008-01-23
AU2003301585A1 (en) 2004-05-13
JP4890763B2 (ja) 2012-03-07
KR20050046015A (ko) 2005-05-17
TWI324070B (en) 2010-05-01
JP2006507816A (ja) 2006-03-09
WO2004037984A2 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
ATE485366T1 (de) Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
Chay et al. A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines
Guinea-Viniegra et al. Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17
WO2003089457A3 (en) Peptide inhibitors of protein kinase c ϝ for pain management
DE60233574D1 (de) Verfahren und zusammensetzungen zum nachweis des aktivierungszustands multipler proteine in einzelzellen
ATE474052T1 (de) Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose
ATE384740T1 (de) Nukleinsäuren, polypeptide und verfahren zur modulierung der apoptose
DE602004017426D1 (de) Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression
DE60130797D1 (de) Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose
IL149922A (en) Tweak receptor antagonist for use in regulating the angiogenesis process, a nucleic acid encoded by the antagonist, expression and host cells that contain the expression carrier and the antagonist to produce the antagonist
ATE449869T1 (de) Verfahren zur beurteilung der wirksamkeit von chemotherapeutika
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
IL179441A (en) Method of measuring the activity of egln enzyme and of identifying an agent that modulates activity of said enzyme
ATE275919T1 (de) Verwendung von metall-proteinase-inhibitoren, um das wachstum der haare oder körperhaare zu induzieren und/oder zu stimulieren und/oder den haarausfall zu verlangsamen
DeTemple et al. Effects of mammalian target of rapamycin inhibitors on cytokine production and differentiation in keratinocytes
ATE466938T1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
ATE506073T1 (de) Verfahren zur modulation der angiogenese mittels der tyrosin kinase src
DE602004030824D1 (de) An der oberfläche befindliche campylobacter jejuni-polypeptide
DE60130565D1 (de) Pde8a und seine verwendung
Denhardt Osteopontin expression correlates with melanoma invasion
Chua et al. Upregulation of endothelin-1 production by lysophosphatidic acid in rat aortic endothelial cells
DE69635925D1 (de) Verfahren und testsatz zur evaluierung der metastasierungstendenz von tumoren
ATE543429T1 (de) Verfahren zur bestimmung des sympathikus-tonus und messsystem dafür
Ikebe et al. NF-κB involvement in tumor–stroma interaction of squamous cell carcinoma
ATE422896T1 (de) Eg-vegf/prokineticin 2 rezeptor antagonisten

Legal Events

Date Code Title Description
8332 No legal effect for de